Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

OVID Ovid Therapeutics Inc. Common Stock
$1.65 4.11% +0.07
Notify me if price changes either direction
Interactive Brokers Logotype

Buy OVID stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 112.5M
Enterprise value 102.1M
Trailing PE -4.4594594594595
Forward PE -4.3097644
PEG Ratio 0.2972972972973
Enterprise to EBITDA -2.642
Enterprise to revenue 15.446
Price to book MRQ 2.5477707
Price to sales TTM 17.237484

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 6.6M
EBITDA -38652000
Diluted EPS TTM -0.5
Total Cash (MRQ) 25.6M
Current ratio (MRQ) 4.241
Operating Cash Flow (TTM) -37934000

OVID trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent OVID News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.